Accelerate your therapeutics program with Unravel
We believe in solving complex disorders
Sharing is caring. Our cutting edge platform is not just for our own therapeutics programs. By partnering with biotechs and pharma, we collaboratively bring about a seachange in patient care. We now offer access to our platform and capabilities. To explore collaboration, contact us using the button below.
Patient advocacy groups, healthcare institutions, physicians, and patients partner with us through the rareSHIFT™ program to accelerate their path to clinical impact and codevelop therapeutics. To learn more, click the button below.
Our Capabilities
Explore our capabilities across the development pipeline, designed to accelerate drug development a produce the most effective therapeutics.
-
Evaluate asset function at individual patient resolution using in silico clinical trials, capturing population-level heterogeneity that traditional approaches may miss.
-
Use the BioX™ platform to identify companion diagnostics and drug response biomarkers, significantly de-risking Phase II and III trials while offering strategic IP potential and commercial partnering opportunities.
-
Evaluate an asset’s efficacy with evidence rooted in patient-biology to support the decision to advance/pause/or kill an asset prior to the investment of millions.
-
Rationally design preclinical model strategy by comparing preclinical models to real patient populations, identifying the models that offer the highest predictive value for the patient population. Simulating preclinical model drug response and comparing to patients derisks a common challenge in traditional drug development: every failed clinical trial had positive preclinical data.
-
Noninvasively collect patient RNA to monitor in real-time the molecular networks underpinning drug efficacy and adverse effects mechanisms.
-
Evaluate the robustness and context of expected mechanisms of action as a function of dose and indication. Discover previously unknown underlying mechanisms of action, including differentiation from new assets from marketed products.
-
Identify off-target mechanisms early.
-
Evaluate assets for additional patents and Orphan Drug Designation, as seen with Unravel’s own success in Rett syndrome.
-
Evaluate whether an asset’s proposed mechanisms are reflected in real patients prior to acquisition.
-
Use longitudinal sampling to understand the combined efficacy of assets to determine complementary mechanisms.
-
Computationally assess the effect of the knockdown or over expression of ~8,000 genes individually on a patient’s genome.
-
Each asset is screened against Unravel's datamine to find expansion opportunities in genetic disorders, inflammatory diseases, metabolism, or oncology. Patient populations with a high prevalence of drug responders are identified, while disorders with a primarily adverse effect probability are flagged.
-
The proprietary nasal swab-based RNA collection allows for non-invasive, home-based sampling from patients worldwide without a cold chain. This technology enables inclusion of diverse, global patient populations that were previously unreachable, and can offer a low-risk exploration of new geographic markets. rareSHIFT™
“If everyone is moving forward together, then success takes care of itself.”
— Henry Ford
